Prostate cancer drug market will double in value in next decade

PR NEWSWIRE: The launch and uptake of nine emerging therapies will drive the prostate cancer drug market to more than double, from nearly $4 billion in 2009 to $8.4 billion in 2019 in the US, France, Germany, Italy, Spain, the UK and Japan. READ MORE>

Read Full Post »

New chemo drug for advanced prostate cancer approved by FDA

WALL ST JOURNAL: The US Food and Drug Administration has approved Jevtana, a chemotherapy drug used in combination with the steroid prednisone to treat men with advanced prostate cancer. READ MORE> and HERE>

Read Full Post »

Canadians develop new drug to shrink prostate cancer tumours

THE GAZETTE: Canadian scientists have developed an experimental new drug to shrink prostate cancer tumours, based on molecules extracted from a marine sponge collected in New Guinea. READ MORE>.

Read Full Post »

Focus moves to what medicine can do about advanced prostate cancer

NEW PROSTATE CANCER INFOLINK: When it comes to prostate cancer, one of the really key issues taxing the medical oncology community over the past few days has been: “How do we need to start thinking about the future treatment of advanced prostate cancer?” READ MORE> Mike Scott provides a list of new drugs and treatments [...]

Read Full Post »

New once-every-six months hormone therapy for prostate cancer gets European registration

PHARMACY EUROPE: A hormone therapy drug for prostate cancer than can be taken once every six months has successfully completed its European registration procedure and will soon be rolled out for use on patients.

Read Full Post »

New prostate cancer drugs give hope of further life beyond chemotherapy

URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life.

Read Full Post »

Breast and ovarian cancer drugs may also work on prostate cancer

MEDICAL NEWS TODAY: A new type of cancer drug called PARP inhibitors – including a new drug called olaparib that is currently showing promising results in trials as a targeted treatment for inherited forms of breast and ovarian cancer – may also be effective against prostate cancer.

Read Full Post »

New DNA vaccine shown to slow PSA doubling in trial on prostate cancer patients

URO TODAY: US scientists have successfully tested a new DNA vaccine that significantly slows PSA doubling, the signal of a belated return of prostate cancer after treatment.

Read Full Post »

Prostate cancer patients round world being tested with new anti-cancer agent that blocks tumour growth

PSA RISING.COM: A potential anti-cancer agent called ZD4054 is being tested in clinical trials around the world in patients with prostate cancer to see if it can block the uptake of endothelin A and thereby shrink tumors or slow their progression.

Read Full Post »

New bone drug likely to get only limited approval for use in prostate cancer patients

NEW YORK TIMES: Denosumab, a new drug to prevent fractures in men undergoing prostate cancer hormone treatment, is likely to get FDA approval for high risk cases only.

Read Full Post »